Insider transaction
Labcorp Holdings Inc. (NYSE: LH) reported that Peter J. Wilkinson, the company's Senior Vice President and Chief Accounting Officer, sold 1,633 shares of common stock on March 27, 2026. The shares were sold at $267.05 each, producing aggregate proceeds of $436,092. The company’s stock was trading near $266 at the time of the report, with Labcorp carrying a market capitalization of $21.97 billion and a price-to-earnings ratio of 25.54.
Regulatory filing and plan details
According to a Form 4 filing with the Securities and Exchange Commission, the disposition was made pursuant to a trading plan established under Rule 10b5-1. The filing indicates the sale followed the structure of an approved plan, rather than being an ad hoc open-market sale.
Related equity movements tied to performance awards
The filings also show activity on March 26, 2026: Wilkinson acquired 2,388 shares of common stock with a reported value of $0 as part of a performance award originally granted on February 7, 2023. That award related to company performance over the three-year period ended December 31, 2025. On the same date, 755 shares were withheld to satisfy tax obligations at a per-share value of $268.38, producing an aggregate tax-withholding amount of $202,626.
Recent operating results and strategic moves
Labcorp reported fourth-quarter 2025 results that showed earnings per share of $4.07, above the consensus expectation of $3.93. Revenue for the period came in at $3.52 billion, short of the $3.56 billion that had been forecast. In a separate strategic initiative, Labcorp expanded its collaboration with PathAI to implement the AISight Dx digital pathology platform across its national network of anatomic pathology laboratories and hospital partnerships. The AISight Dx platform is described as an FDA-cleared, cloud-based system intended to support digital slide management and diagnostic workflows.
Leadership developments
Labcorp also disclosed that Glenn Eisenberg, the company’s former Executive Vice President and Chief Financial Officer, has been added to the board of directors of The Middleby Corporation. Following his retirement in December 2024, Eisenberg will assume the role of Special Advisor at Middleby.
Additional resources
The filing notice included a reference to InvestingPro subscribers, noting that those users have access to more than 10 additional ProTips for Labcorp and detailed Pro Research Reports that cover this company and over 1,400 other U.S. equities.
Summary points
- Wilkinson sold 1,633 Labcorp shares on March 27, 2026, at $267.05 per share, totaling $436,092.
- The sale was executed under a Rule 10b5-1 trading plan, according to an SEC Form 4 filing.
- Labcorp’s Q4 2025 EPS beat consensus while revenue slightly missed forecasts; the company expanded its PathAI AISight Dx deployment and announced a board appointment at The Middleby Corporation.
Contextual notes
The information presented reflects the transactions and corporate developments recorded in the SEC filing and company announcements. Where values, dates, and amounts are reported above, they are drawn directly from those disclosures.